
Ipamorelin 5mg Growth Factors
The cleanest GH secretagogue.
The cleanest secretagogue on the market. Full selectivity on ghrelin receptors — no cortisol, no prolactin, no unwanted appetite spike. Pure, targeted stimulation of the GH axis. The premium pick for zero-side-effect long-term protocols.
- In stock in France
Ordered with its water: shipped in a magnetic box
10% off every deliveryPause, skip or cancel in 1 clickNo commitment, no hidden fees
No automatic charge: pay for each delivery by card, in Bitcoin (an extra 5% off), or by bank transfer from €100
Your complete kit
The vial alone cannot be used as is. Add what you need to prepare it:
Frequently bought together
Research Use Only (RUO) · Prohibited for human or veterinary use.
Key facts
Our Ipamorelin 5 mg vial is the most selective GHRP (Growth Hormone Releasing Peptide) available in peptide research. Initially developed by Novo Nordisk in the 1990s, Ipamorelin is a pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) selective agonist of the GHS-R1a receptor (ghrelin receptor), responsible for stimulating pulsatile growth hormone secretion without the cross-side effects characteristic of non-selective GHRPs. With 5 mg of lyophilized peptide per vial at HPLC purity ≥98 %, this format covers approximately 10 to 20 days of protocol at the typical 250-500 mcg/day dose. Ipamorelin is the reference GHRP for research protocols seeking to avoid the undesirable increases in cortisol, prolactin, or ACTH reported with GHRP-6 or Hexarelin.
In detail
It is systematically associated with CJC-1295 DAC in secretagogue literature to explore the GHRH + GHRP synergy on GH pulsatility. The flexible pilot format to document a first secretagogue response.
Protocol and preparation
| Water added | Concentration | Reading marker |
|---|---|---|
| 1 ml | 5 mg/ml | 40 UI = 2 mg |
| 2 ml | 2,5 mg/ml | 40 UI = 1 mg |
The volume of water does not change the product, only its concentration. Introduce the water slowly along the vial wall, never directly onto the lyophilisate, then swirl without shaking. Markers given on a 1 ml syringe graduated in 100 units.
Asepsis
Disinfect surfaces and stoppers (70% alcohol).
Solvent
Draw the required volume of bacteriostatic water.
Introduction
Inject gently against the vial wall (avoid direct jet on powder).
Solubilization
Roll the vial gently. Do not shake vigorously (degradation risk).
Solution storage Once reconstituted: 2-8°C (refrigerator).
Warning Theoretical tool for chemical handling. Does not constitute medical advice.
Open the dilution calculator- The amount of powder looks tiny. A lyophilisate takes up a few millimetres at the bottom of the vial, sometimes just a translucent film. The stated weight is there.
- The powder is compact, stuck to the wall or to the stopper. Transport moves the freeze-dried cake around. It changes nothing to reconstitution.
- The vial carries no individual label. That is our standard packaging, not a downgraded vial.
- After reconstitution, deposits or filaments appear. This is common, especially with small molecules. Let it settle and roll the vial between your palms, never shake it.
- The parcel is plain. Nothing on the outside indicates the contents or the brand name.
What is not normal: a cracked vial, an uncrimped cap or a stopper that moves, powder that has liquefied or changed colour. In those specific cases, write to us with a photo and we take the vial back.
Recommended reconstitution: 2 ml bacteriostatic water for injection → final concentration 2.5 mg/ml. Alternative volume: 1 ml (5 mg/ml, for high doses). Procedure: 1) let vial and diluent reach room temperature (15 minutes); 2) disinfect stopper with 70% alcohol; 3) draw bacteriostatic water into sterile syringe; 4) inject slowly along inner wall of vial; 5) gently swirl until dissolution — no vigorous shaking. Dosages reported in literature: exploratory human research protocols (outside authorized therapeutic framework) typically mention 200 to 300 mcg per injection, 2 to 3 times daily subcutaneously, or 400-900 mcg/day total. Some protocols explore higher doses (500 mcg x 3/day = 1500 mcg/day). At 2.5 mg/ml concentration, 200 mcg corresponds to 0.08 ml (8 units on 100 IU syringe), 300 mcg to 0.12 ml (12 units), and 500 mcg to 0.2 ml (20 units). Documented optimal timing: injections are typically placed away from meals (2 hours before or after a carbohydrate- or lipid-rich meal that may attenuate GH response). Classic moments are: morning fasted, pre-workout, before bedtime. Autonomy: 5 mg allows approximately 5 days at 300 mcg x 3/day (~900 mcg/day), or less than one week. For an extended 6-8 week protocol at this regimen, plan for 8 to 10 vials. Documented synergy with CJC-1295 DAC: the CJC-1295 DAC (1 mg/week) + Ipamorelin (200-300 mcg x 2-3/day) combination is the most studied secretagogue protocol, exploiting the GHRH-R + GHS-R1a synergy to amplify GH pulsatility without cortisol/prolactin effects. Post-reconstitution storage: refrigerator 2-8 degrees Celsius, 28-day usage window with bacteriostatic.
Technical data
- Reconstitution
- 2 ml d'eau → 2,5 mg/ml. 8 UI = 200 mcg ; 12 UI = 300 mcg.
- Peptide sequence
- Aib-His-D-2-Nal-D-Phe-Lys-NH2
- Molecular formula
- C38H49N9O5
- Molecular weight
- 711.9 g/mol
- CAS number
- 170851-70-4
- Physical form
- Poudre lyophilisée
- Recommended solubility
- Eau bactériostatique, NaCl 0,9%
- Storage conditions
- Au réfrigérateur (+2 à +8 °C), à l'abri de la lumière. En poudre, possible au congélateur pour une conservation longue. Une fois préparé : réfrigérateur, jamais au congélateur.
- Use
- Research reagent, in vitro only (RUO)
Storage & handling
Lyophilized unreconstituted Ipamorelin is stored in the fridge (+2 to +8 °C) in its original sealed packaging, protected from light and humidity; for long-term storage (over 3 months), a -20 °C freezer keeps it for up to 24 months. At refrigerated temperature (2-8 degrees Celsius), documented stability covers a minimum of 12 months. At room temperature (below 25 degrees Celsius), recommended duration for transport or temporary storage: 3 weeks maximum. Once reconstituted with bacteriostatic water, Ipamorelin must be stored between 2 and 8 degrees Celsius. Documented post-reconstitution stability: 28 days with bacteriostatic (benzyl alcohol 0.9%), 7 days with preservative-free sterile water. Specific sensitivities: like all short pentapeptides, Ipamorelin is sensitive to repeated freeze-thaw cycles (limit to a maximum of three), histidine oxidation (avoid contact with non-inert metals), and prolonged acidic or basic hydrolysis. Avoid direct UV exposure and thermal shocks. Lyophilised Ipamorelin shows excellent stability at -20°C under desiccation (> 24 months with no measurable RP-HPLC purity loss). In reconstituted solution (0.9% benzyl alcohol bacteriostatic water, 1-5 mg/mL), documented 28-day stability at 2-8°C in amber vial. Optimal pH is 5.5-7.0: avoid highly acidic (pH < 4) or basic (pH > 8) solutions favouring deamidation of C-terminal Lys-NH2 residue and hydrolysis of D-Phe-Lys amide bonds. N-terminal Aib confers superior exopeptidase resistance but remains sensitive to oxidative conditions: strictly protect from UV light and avoid exposure to residual hydrogen peroxide in diluents. Unlike more complex peptides, Ipamorelin contains no Cys (no disulfide dimer risk) nor Met (no oxidation), simplifying storage logistics. Repeated freeze/thaw cycles must be avoided as they generate aggregates detectable by SEC-HPLC.
Mechanism of action
Ipamorelin is a synthetic pentapeptide with sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2 (amino-isobutyric acid - histidine - D-naphthylalanine - D-phenylalanine - amidated lysine), molecular weight 711.85 Da. The sequence integrates non-natural residues (Aib, D-2-Nal, D-Phe) conferring increased metabolic stability and optimizing affinity for the target receptor.
At the molecular level, Ipamorelin is a selective agonist of the GHS-R1a receptor (Growth Hormone Secretagogue Receptor 1a), also known as the ghrelin receptor. This Gq/11-coupled receptor is expressed primarily in somatotropic cells of the anterior pituitary and in certain hypothalamic areas (arcuate nucleus, paraventricular nucleus). Receptor activation triggers a PLC-IP3-Ca2+ cascade leading to rapid pulsatile release of GH stored in secretion granules.
The distinctive characteristic of Ipamorelin is its exceptional SELECTIVITY: unlike other GHRPs (GHRP-6, GHRP-2, Hexarelin), Ipamorelin does NOT induce significant increases in prolactin, cortisol, ACTH, or aldosterone at studied therapeutic doses. This selectivity was documented in the foundational Raun et al. study (1998) and confirmed by subsequent independent work. It makes Ipamorelin the preferred GHRP for research protocols where GH effect specificity is a priority.
Pharmacokinetically, Ipamorelin presents a short plasma half-life of approximately 2 hours, with a GH peak observed 30-45 minutes after subcutaneous injection. This rapid kinetics requires multi-daily administrations (2-3 times per day) to maintain chronic stimulation, typically in synergy with an extended-duration GHRH analog such as CJC-1295 DAC.
Preclinical and exploratory human studies have documented GH increases of 5 to 15 times baseline after injection, with return to baseline values in 3-4 hours. IGF-1 increases 1.5 to 2 times baseline after 1-2 weeks of regular protocol. Ipamorelin is not approved for human therapeutic use and remains an exploratory research tool.
Structurally, Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2, 711.9 Da) designed by NovoNordisk in collaboration with Ferring in the mid-1990s as a selective tool for the GHS-R1a receptor (Growth Hormone Secretagogue Receptor type 1a). Two key structural features distinguish it from other GHRPs: (1) incorporation of an α-aminoisobutyric residue (Aib) at position 1 replacing the histidine of classical GHRPs, stabilising the β-turn conformation required for receptor activation, (2) presence of a D-2-naphthyl-alanine (D-2-Nal) at position 3 replacing the D-isomer tryptophan, increasing GHS-R1a selectivity over related receptors. Pharmacologically this yields a highly selective GHS-R1a agonist which, in classical rodent studies (Raun et al., Eur J Endocrinol 1998), does not significantly elevate cortisolemia, ACTH, prolactin or FSH/LH at effective doses, unlike GHRP-2 and GHRP-6. This "clean" selectivity makes Ipamorelin the reference tool to specifically isolate the ghrelin-like effect on the somatotropic axis. Signalling activates PLC-β → DAG + IP3 → intracellular Ca²⁺ + PKC (via Gαq) plus Gαs-cAMP-PKA, with a balanced profile neither Gαs- nor β-arrestin-biased in recent cryo-EM and BRET studies (2020-2023).
Studies and references
The scientific corpus on Ipamorelin primarily comes from the founding work of the Raun group (Novo Nordisk) in the 1990s, then from European and American academic teams studying the selective GHRP class.
Raun et al. (European Journal of Endocrinology 1998; DOI 10.1530/eje.0.1390552) published the foundational study on Ipamorelin, documenting in rat and dog a dose-dependent GH stimulation without significant increase in prolactin, cortisol, or ACTH — unlike GHRP-6 and GHRP-2 studied in the same protocol. This study established Ipamorelin as the first GHRP with pure GH selectivity.
Gobburu et al. (Journal of Clinical Pharmacology 1999) conducted the first pharmacokinetic studies in healthy humans, documenting biphasic kinetics, subcutaneous bioavailability, and absence of significant adverse effects after single injection. The 2h half-life and 30-45 min GH peak were confirmed.
Gonzalez-Lopez et al. (Growth Hormone & IGF Research 2000) explored the chronic response of the somatotropic axis under Ipamorelin administered 2-3 times daily for 4 weeks in adult rats, documenting a sustained IGF-1 increase without notable GHS-R1a receptor desensitization.
Beck et al. (Hormone Research 2001) studied the Ipamorelin + GHRH 1-29 combination in dogs, providing the first data on GHRP + GHRH synergy that would later be explored with CJC-1295 DAC. GH increase was significantly superior to the sum of individual effects.
Several human phase 2 clinical trials (indicationsPost-operative ileus, cachexia, elderly undernutrition) were conducted between 2000 and 2010 by various sponsors. Results showed good tolerance but mixed clinical efficacies, leading to discontinuation of most commercial programs. Helixmith/Bachem currently holds rights on certain research indications.
Corpus limitationsHuman studies are essentially phase 1-2 with cohorts <100 subjects, long-term data (>6 months) are rare, and no marketing authorization has been obtained. Ipamorelin remains strictly an exploratory research peptide outside validated clinical protocols.
Ipamorelin preclinical models cover acute GH stimulation, lean mass preservation in cachexia and post-operative healing. In young Sprague-Dawley rats, SC bolus 5-50 µg/kg: plasma GH peak reaching 100-300 ng/mL at 10-15 min, return to baseline at 60-90 min, without significant elevation of cortisol, ACTH, prolactin or FSH/LH at rodent therapeutic doses (Raun 1998). In ovariectomised (OVX) rats: chronic administration 4-6 weeks preserves trabecular bone mineral density (µCT) and femoral mechanical strength (3-point bending). In C26 tumor cachexia model in BALB/c mice: partial preservation of lean mass quantified by DEXA and reduced weight loss vs untreated control. In postoperative ileus model in dogs and pigs (Helsinn Therapeutics studies leading to subsequent clinical trials — phase III program discontinued): Ipamorelin favours digestive motility recovery via central GHS-R1a action and peripheral action on myenteric plexuses. In aged rat model (18-24 months): plasma IGF-1 elevation partially restoring juvenile levels over 4-8 weeks, notably in co-administration with CJC-1295 (DAC or non-DAC). All these data are preclinical (RUO), no therapeutic human use authorised.
- 1Sécrétagogue GHIpamorelin, the first selective growth hormone secretagogue
- 2
Similar peptides
Ipamorelin occupies a unique position in the GHRP (Growth Hormone Releasing Peptides) class thanks to its exceptional selectivity on the GHS-R1a receptor without undesirable effects on corticotropic, lactotropic, or mineralocorticoid axes.
Compared to GHRP-6 (the first widely used GHRP), Ipamorelin offers a significantly cleaner profile: GHRP-6 substantially increases prolactin, cortisol, and stimulates hunger via its central orexigenic effect. Ipamorelin preserves the adjacent hormonal profile while providing comparable GH stimulation at equipotent dose.
Compared to GHRP-2 (improved GHRP-6 evolution), Ipamorelin remains more selective: GHRP-2 still produces a slight prolactin increase and modest cortisol stimulation. GH response amplitude is similar between the two peptides.
Compared to Hexarelin (historically the most potent GHRP), Ipamorelin avoids the rapid desensitization and marked cortisol and prolactin increases reported with Hexarelin in prolonged use. Hexarelin retains its interest in short protocols where potency outweighs selectivity.
Compared to MK-677 (Ibutamoren, non-peptide oral secretagogue), Ipamorelin presents a more physiological pulsatile kinetics (peak-return-peak) versus MK-677 which produces a sustained non-pulsatile elevation that may desensitize the receptor long-term. Ipamorelin however requires daily injections, against a single oral dose for MK-677.
In synergy with CJC-1295 DAC (extended-duration GHRH analog), Ipamorelin forms the most studied secretagogue duo in literature, exploiting the two independent GHRH-R + GHS-R1a pathways to maximize physiological GH pulsatility. This combined protocol remains the gold standard in secretagogue research.
In our shop, Ipamorelin is the most ordered GHRP, thanks to its selectivity profile. Its commercialization for human therapeutic use remains prohibited in France, Europe, and the United States — strict research use.
Ipamorelin stands out from other GHRPs by its exceptionally selective activity profile. Compared to GHRP-2 (D-Ala-D-β-Nal-Ala-Trp-D-Phe-Lys-NH2, 817 Da): Ipamorelin induces similar GH release but without detectable cortisol, ACTH or prolactin elevation at effective doses, while GHRP-2 modestly elevates these hormones at high doses. Compared to GHRP-6 (His-D-Trp-Ala-Trp-D-Phe-Lys-NH2, 872 Da): Ipamorelin has no significant orexigenic effect (GHRP-6 strongly activates food intake via hypothalamic POMC/NPY). Compared to Hexarelin (His-D-2-MeTrp-Ala-Trp-D-Phe-Lys-NH2, 887 Da): Ipamorelin does not activate the CD36 receptor expressed on cardiomyocytes, while hexarelin shows a CD36-mediated cardiotropic effect in rodent ischaemia models. Compared to MK-677 (ibutamoren): Ipamorelin is peptide and SC injectable with acute kinetics (~90 min), MK-677 is oral with 24h chronic kinetics — complementary pharmacological tools. Compared to GHRH analogues (sermorelin, CJC-1295 with or without DAC, tesamorelin): different mechanism (GHS-R1a Gαq/Gαs vs GHRHR Gαs), systematically documented supra-additive synergy in co-administration. In research protocols, Ipamorelin + CJC-1295 (non-DAC) is the preferred combination for reconstituted physiological GH pulsatility studies.
Frequently asked questions
Why is Ipamorelin the most selective GHRP?
How do I reconstitute Ipamorelin 5 mg?
Why combine Ipamorelin with CJC-1295 DAC in research?
Which biological markers are tracked in Ipamorelin protocols?
Is your Ipamorelin authentic?
What is the delivery lead time in Europe?
What is the documented tolerance profile?
How long does a 5 mg vial cover in protocol?
Why is Ipamorelin considered the 'cleanest' GHRP?
What is Ipamorelin's plasma half-life in rodents?
Ipamorelin + CJC-1295: which combination to recommend in research?
The complete guideCJC-1295: complete guide to DAC vs no DAC (Mod GRF 1-29) in researchCJC-1295 with or without DAC: structure, half-life (8 days versus 30 minutes), GH pulsatility, the Teichman and Ionescu 2006 trials, the ipamorelin combination, comparison with sermorelin and tesamorelin, and reconstitution.Read the guide Also read:Ipamorelin: complete guide to the selective GHRP (studies, dosing, status)Solid-phase peptide synthesis (SPPS): complete guide to Merrifield, Fmoc, Boc, resins, coupling reagents and quality control
